Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 694Neoplasms 612Prostatic Neoplasms 315Lung Neoplasms 308Colorectal Neoplasms 280Carcinoma, Non-Small-Cell Lung 254Pancreatic Neoplasms 178Carcinoma, Hepatocellular 168Stomach Neoplasms 139Multiple Myeloma 127Ovarian Neoplasms 120Melanoma 118Colonic Neoplasms 112Brain Neoplasms 108Hematologic Neoplasms 107Head and Neck Neoplasms 106Urinary Bladder Neoplasms 103Leukemia, Myeloid, Acute 102Esophageal Neoplasms 101Disease 100Uterine Cervical Neoplasms 88Neoplasm Metastasis 88Liver Neoplasms 88Rectal Neoplasms 85Lymphoma 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Endometrial Neoplasms 76Carcinoma, Renal Cell 73Leukemia 63Recurrence 62

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Urothelial Cancer × 1 year × Clear all
NCT07207928 2026-01-09

AvePem

Azienda Ospedaliera Universitaria Integrata Verona

Completed
35 enrolled
Genitourinary

Urothelial Cancer

NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡